Cardiogen

Cardiogen is a short peptide bioregulator from the Khavinson family, developed at the Saint Petersburg Institute of Bioregulation and Gerontology for cardiovascular applications. The compound is reported to target cardiac myocytes and the coronary vascular endothelium, with proposed effects including improved myocardial metabolism, restoration of age-related decline in cardiac contractility, and modulation of cardiac remodeling processes. Like other Khavinson bioregulators, it is presumed to act through tissue-specific gene-expression modulation at promoter regions in cardiac cells.

Russian clinical-observational studies have evaluated Cardiogen in elderly patients with coronary artery disease, post-myocardial infarction recovery, and heart failure with preserved ejection fraction. Reported outcomes have included improvements in exercise capacity, reduction in anginal episodes, and improvements in subjective cardiac function. The clinical evidence is primarily Russian observational rather than randomized controlled trial.

Cardiogen is sold by research-chemical vendors outside Russia. Western clinical data is essentially absent, and the compound is best understood as research-grade with a Russian observational clinical track record. It should not be used as a substitute for evidence-based cardiac medications.

Cardiogen was developed in the early 2000s as part of the Khavinson group's systematic program of identifying tissue-specific bioregulator peptides. The cardiovascular member of the family was based on bioactive fractions of bovine cardiac tissue extracts, with the active short peptide sequence subsequently identified and synthesized. The compound entered Russian clinical use in the mid-2000s.